NTI endorses the bipartisan Biosecurity Modernization and Innovation Act of 2026, led by Senators Tom Cotton (R-AR) and Amy Klobuchar (D-MN). This bill creates an important opportunity to incentivize a safe and secure U.S. bioeconomy through strengthened biosecurity policy.
“The Biosecurity Modernization and Innovation Act represents a critical opportunity to embed biosecurity into the foundation of America’s strong and growing bioeconomy. By modernizing oversight and fostering collaboration across government, industry, and academia, this legislation helps ensure that scientific and technological progress will strengthen—not jeopardize—national and global security.”
— Hayley Anne Severance, acting vice president, NTI | bio
The legislation advances three core objectives essential to safeguarding innovation:
- Strengths DNA synthesis sequence and customer screening as a near-term risk-reduction measure
- Establishes an innovation hub within the U.S. government that brings together commercial, academic, and government stakeholders to develop, test, and deploy real-world solutions that embed biosecurity by design
- Streamlines and strengthens federal oversight of dual-use bioscience and biotechnology research and development to protect against accidental or deliberate harmful activities, forming core pillars of a comprehensive national biosafety and biosecurity strategy.
The bill offers solutions to close gaps in U.S. biotechnology oversight and aligns closely with NTI | bio recommendations for Congressional action. By consolidating and modernizing fragmented approaches to biosecurity and biosafety, the legislation will enable responsible scientific progress, reinforce U.S. biotechnology leadership, and strengthen national and global security.